Recently, target immunotherapy using PD-1 and PD-L1 monoclonal antibodies (MoAbs) was demonstrated to significantly induce durable tumor regression and prolong disease stabilization in patients with selected advanced cancers, including non–small cell lung cancer, a tumor considered to be non-responsive to immunotherapy [39,49]. The gene discussed is CD274; the disease is cancer.